Products Categories
| CAS No.: | 25322-68-3 |
|---|---|
| Name: | Poly(ethylene glycol) |
| Article Data: | 9 |
| Molecular Structure: | |
|
|
|
| Formula: | C2nH4n+2On+1 |
| Synonyms: | Glycols, polyethylene;Glycols,polyethylene (8CI);AlkoxE 130;Alkox E 30;Alkox E 30G;Alkox R 100;Alkox R 15;Alkox R 400;Alkox SW;AquaCalk TWB-P;Aquaffin;Badimol;Breox 20M;Breox PEG 300;CBP 20;Carbowax 14000;Carbowax 1450;Carbowax 1500;Carbowax 4500;Carbowax E 300;CarbowaxSentry NF;Cartaretin E;Cerasol 250A;Chemiox E20(C);Gligogum 4000;H 22;HM 500;HPEO 4250;IW;KPEG 6000;KleanPrep;L 6;Laprol 1001;Polyethylene glycol; |
| EINECS: | 203-473-3 |
| Density: | 1.27 g/mL at 25 °C |
| Melting Point: | 64-66 °C |
| Boiling Point: | >250 °C |
| Flash Point: | 270 °C |
| Solubility: | Water soluble |
| Appearance: | White waxy crystalline flakes |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/38 |
| Safety: | 26-36-24/25 |
| PSA: | 40.46000 |
| LogP: | -1.02900 |
What can I do for you?
Get Best Price
The Poly(ethylene oxide), with the CAS registry number 25322-68-3, is also known as 1,2-Ethanediol homopolymer. It belongs to the product categories of Polymers; Optimization Reagents; Protein Structural Analysis; X-Ray Crystallography; Cosmetic Ingredients & Chemicals; Gas Chromatography; Packed GC; Stationary Phases; Homobifunctional PEG; Poly(ethylene glycol) (PEG) and PEG Solutions; Poly(ethylene glycol) and Oligo(ethylene glycol); Essential Chemicals; Inorganic Salts; Materials Science; Poly(ethylene glycol) and Poly(ethylene oxide); Research Essentials; Solutions and Reagents. This chemical's molecular formula is C2nH4n+2On+1. This chemical is a polyether compound with many applications from industrial manufacturing to medicine.
Physical properties about Poly(ethylene oxide) are: (1)ACD/LogP: 0.046; (2)ACD/LogD (pH 5.5): -2.42; (3)ACD/LogD (pH 7.4): -2.48; (4)ACD/BCF (pH 5.5): 1.00 ; (5)ACD/BCF (pH 7.4): 1.00; (6)ACD/KOC (pH 5.5): 1.00; (7)ACD/KOC (pH 7.4): 1.00; (8)#H bond acceptors: 4; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 8; (11)Index of Refraction: 1.477; (12)Molar Refractivity: 48.833 cm3; (13)Molar Volume: 172.896 cm3; (14)Polarizability: 19.359 10-24cm3; (15)Surface Tension: 43.2919998168945 dyne/cm; (16)Density: 1.083 g/cm3; (17)Flash Point: 169.77 °C; (18)Enthalpy of Vaporization: 66.181 kJ/mol; (19)Boiling Point: 357.104 °C at 760 mmHg
Preparation of Poly(ethylene oxide): Poly(ethylene oxide) is produced by the interaction of ethylene oxide with water, ethylene glycol, or ethylene glycol oligomers.[5] The reaction is catalyzed by acidic or basic catalysts. Ethylene glycol and its oligomers are preferable as a starting material instead of water, because they allow the creation of polymers with a low polydispersity (narrow molecular weight distribution). Polymer chain length depends on the ratio of reactants.
HOCH2CH2OH + n(CH2CH2O) → HO(CH2CH2O)n+1H
Uses of Poly(ethylene oxide): It is used as an excipient in many pharmaceutical products. Moreocer, it is used in conjunction with carbon black to form a conductive composite. This product should be sealed and stored in a cool, ventilated and dry place. Moreover, it is heat-stable and inert to many chemical agents and will not hydrolyze or deteriorate under normal conditions.
When you are using this chemical, please be cautious about it as the following: This chemical is irritating to eyes and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. When using it, you need wear suitable protective clothing and you must avoid contact with skin and eyes.
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LDLo | intravenous | 3gm/kg (3000mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 103, Pg. 293, 1951. | |
| guinea pig | LD50 | oral | 15700mg/kg (15700mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| guinea pig | LD50 | oral | 17gm/kg (17000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| guinea pig | LD50 | oral | 19600mg/kg (19600mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| guinea pig | LD50 | oral | 22500mg/kg (22500mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 39, Pg. 349, 1950. | |
| guinea pig | LD50 | oral | 28gm/kg (28000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| guinea pig | LD50 | oral | 28900mg/kg (28900mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| guinea pig | LD50 | oral | 50gm/kg (50000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| guinea pig | LD50 | oral | 50900mg/kg (50900mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| mouse | LD50 | intraperitoneal | 473mg/kg (473mg/kg) | Yaoxue Tongbao. Bulletin of Pharmacology. Vol. 21, Pg. 387, 1986. | |
| mouse | LD50 | intraperitoneal | 2gm/kg (2000mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Journal of Pharmacology and Experimental Therapeutics. Vol. 103, Pg. 293, 1951. |
| mouse | LD50 | intraperitoneal | 7500mg/kg (7500mg/kg) | National Technical Information Service. Vol. AD628-313, | |
| mouse | LD50 | intraperitoneal | 8gm/kg (8000mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Journal of Pharmacology and Experimental Therapeutics. Vol. 103, Pg. 293, 1951. |
| mouse | LD50 | intravenous | 7900ug/kg (7.9mg/kg) | Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 316, 1970. | |
| mouse | LD50 | intravenous | 8550mg/kg (8550mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 1581, 1976. | |
| mouse | LD50 | intravenous | 16gm/kg (16000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| mouse | LD50 | oral | 28915mg/kg (28915mg/kg) | Proceedings of the European Society of Toxicology. Vol. 17, Pg. 351, 1976. | |
| mouse | LD50 | oral | 31gm/kg (31000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| mouse | LD50 | oral | 34gm/kg (34000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| mouse | LD50 | oral | 36gm/kg (36000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| mouse | LD50 | subcutaneous | 18gm/kg (18000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rabbit | LD | skin | > 1gm/kg (1000mg/kg) | Union Carbide Data Sheet. Vol. 9/25/1969, | |
| rabbit | LD50 | intravenous | 8gm/kg (8000mg/kg) | BLOOD: CHANGE IN CLOTTING FACTORS | Kriobiologiya i Kriomeditsina. Cryobiology and Cryomedicine. Vol. 4, Pg. 71, 1978. |
| rabbit | LD50 | oral | 14gm/kg (14000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| rabbit | LD50 | oral | 17300mg/kg (17300mg/kg) | International Journal of Toxicology. Vol. 18(Suppl, | |
| rabbit | LD50 | oral | 17300mg/kg (17300mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rabbit | LD50 | oral | 19gm/kg (19000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| rabbit | LD50 | oral | 26800mg/kg (26800mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rabbit | LD50 | oral | 28900mg/kg (28900mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rabbit | LD50 | oral | 76gm/kg (76000mg/kg) | International Journal of Toxicology. Vol. 18(Suppl, | |
| rabbit | LD50 | oral | 76gm/kg (76000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rabbit | LD50 | skin | > 20mL/kg (20mL/kg) | International Journal of Toxicology. Vol. 18(Suppl, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-1112, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-2202, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-96, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-2203, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-937, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-939, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-935, | |
| rabbit | LD50 | skin | > 20gm/kg (20000mg/kg) | Dow Chemical Company Reports. Vol. MSD-940, | |
| rat | LD | oral | > 4gm/kg (4000mg/kg) | Union Carbide Data Sheet. Vol. 9/25/1969, | |
| rat | LD50 | intraperitoneal | 6790mg/kg (6790mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 9gm/kg (9000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 9700mg/kg (9700mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3849, 1982. | |
| rat | LD50 | intraperitoneal | 9708mg/kg (9708mg/kg) | Proceedings of the European Society of Toxicology. Vol. 17, Pg. 351, 1976. | |
| rat | LD50 | intraperitoneal | 12600mg/kg (12600mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 14100mg/kg (14100mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3849, 1982. | |
| rat | LD50 | intraperitoneal | 15390mg/kg (15390mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 15570mg/kg (15570mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 16gm/kg (16000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intraperitoneal | 17gm/kg (17000mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 39, Pg. 349, 1950. | |
| rat | LD50 | intraperitoneal | 17700mg/kg (17700mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | intravenous | 7130mg/kg (7130mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3849, 1982. | |
| rat | LD50 | intravenous | 7312mg/kg (7312mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 1581, 1976. | |
| rat | LD50 | intravenous | 7500mg/kg (7500mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3849, 1982. | |
| rat | LD50 | intravenous | 13gm/kg (13000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 600mg/kg (600mg/kg) | Dow Chemical Company Reports. Vol. MSD-94, | |
| rat | LD50 | oral | 1054mg/kg (1054mg/kg) | Dow Chemical Company Reports. Vol. MSD-95, | |
| rat | LD50 | oral | > 4gm/kg (4000mg/kg) | Dow Chemical Company Reports. Vol. MSD-938, | |
| rat | LD50 | oral | 22gm/kg (22000mg/kg) | "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 747, 1969. | |
| rat | LD50 | oral | 27500mg/kg (27500mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 28gm/kg (28000mg/kg) | Dow Chemical Company Reports. Vol. MSD-1112, | |
| rat | LD50 | oral | 30gm/kg (30000mg/kg) | Dow Chemical Company Reports. Vol. MSD-2203, | |
| rat | LD50 | oral | 30200mg/kg (30200mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 39, Pg. 349, 1950. | |
| rat | LD50 | oral | 31600mg/kg (31600mg/kg) | "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 747, 1969. | |
| rat | LD50 | oral | 31640mg/kg (31640mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 32gm/kg (32000mg/kg) | Dow Chemical Company Reports. Vol. MSD-937, | |
| rat | LD50 | oral | 44200mg/kg (44200mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 45gm/kg (45000mg/kg) | "Patty's Industrial Hygiene and Toxicology," 3rd rev. ed., Clayton, G.D., and F.E. Clayton, eds., New York, John Wiley & Sons, Inc., 1978-82. Vol. 3 originally pub. in 1979; pub. as 2n rev. ed. in 1985.Vol. 2C, Pg. 3847, 1982. | |
| rat | LD50 | oral | 50gm/kg (50000mg/kg) | "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 747, 1969. | |
| rat | LD50 | oral | > 50gm/kg (50000mg/kg) | Dow Chemical Company Reports. Vol. MSD-935, | |
| rat | LD50 | oral | 50gm/kg (50000mg/kg) | "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 747, 1969. | |
| rat | LD50 | oral | > 50gm/kg (50000mg/kg) | Dow Chemical Company Reports. Vol. MSD-940, | |
| rat | LD50 | oral | 50gm/kg (50000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 51200mg/kg (51200mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | oral | 51310mg/kg (51310mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | subcutaneous | 16gm/kg (16000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 451, 1953. |
| rat | LD50 | unreported | 7800mg/kg (7800mg/kg) | United States Patent Document. Vol. #4767763, | |
| rat | LDLo | intravenous | 3mg/kg (3mg/kg) | Toxicology and Applied Pharmacology. Vol. 16, Pg. 442, 1970. | |
| rat | LDLo | intravenous | 22gm/kg (22000mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION KIDNEY, URETER, AND BLADDER: HEMATURIA | Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1087, 1973. |
